4th Quarter - Report

ASSOCIATION FOR ACCESSIBLE MEDICINES for ASSOCIATION FOR ACCESSIBLE MEDICINES

Firm
Client
Income
—
Expenses
$578,464
Expense method
C: businesses, Internal Revenue Code section 162(e)

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

Generic Drug User Fees, Funding for FDA, Funding for the Office of Generic Drugs, FY12 Presidential Budget Request, FY11 and FY12 Budget

LobbyistCovered position, as disclosed
CHRISTOPHER DAVIS —
JAMES M FENTON —
MARK D HENDRICKSON —
JASON R MONEY —
RALPH NEAS New —
JOHN SLOTMAN —

Contacted: Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Patent & Trademark Office (PTO); Congressional Budget Office (CBO); U.S. Trade Representative (USTR); Federal Trade Commission (FTC); HOUSE OF REPRESENTATIVES; SENATE; White House Office; Medicare Payment Advisory Commission (MedPAC); Office of Management & Budget (OMB); Food & Drug Administration (FDA); Commerce, Dept of (DOC)

Trade (domestic/foreign) TRD

Free Trade Agreements-Trans Pacific Partnership, Korean Free Trade Agreement, Anti-Counterfeiting Trade Agreement (ACTA), Generic medicines

LobbyistCovered position, as disclosed
CHRISTOPHER DAVIS —
JAMES M FENTON —
MARK D HENDRICKSON —
JASON R MONEY —
RALPH NEAS New —
JOHN SLOTMAN —

Contacted: Health & Human Services, Dept of (HHS); White House Office; Medicare Payment Advisory Commission (MedPAC); Patent & Trademark Office (PTO); Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Food & Drug Administration (FDA); Congressional Budget Office (CBO); Federal Trade Commission (FTC); Commerce, Dept of (DOC); Office of Management & Budget (OMB)

Copyright/Patent/Trademark CPT

Patent Reform, Patent Settlements/Reverse Payments/Exclusionary Payments, Patent Term Extensions, Generic Drugs H.R.5 Help Efficient, Accessible, Low-cost, Timely Healthcare (Health) Act of 2011 S.23 and H.R.1249 America Invents Act, Sections 10 and 11 (Supplemental Examination) and Section 37 (patent term extension calculation) S.27 Preserve Access to Affordable Generics Act, S.373 Fair Prescription Drug Competition Act S. 1882, the Fair And Immediate Release of Generic Drugs Act

LobbyistCovered position, as disclosed
CHRISTOPHER DAVIS —
JAMES M FENTON —
MARK D HENDRICKSON —
JASON R MONEY —
RALPH NEAS New —
JOHN SLOTMAN —

Contacted: Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); White House Office; Commerce, Dept of (DOC); Office of Management & Budget (OMB); U.S. Trade Representative (USTR); Medicare Payment Advisory Commission (MedPAC); Centers For Medicare and Medicaid Services (CMS); Congressional Budget Office (CBO); Federal Trade Commission (FTC); Patent & Trademark Office (PTO); SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 27 (112th), S. 373 (112th), S. 1882 (112th), S. 23 (112th), H.R. 1249 (112th), H.R. 5 (112th)

Medicare/Medicaid MMM

FY 2012 Budget, Implementation of Health Care Reform, Medicaid Rebates, Prescription Drug Reimbursement, Average Manufacture Price (AMP)/AMP Publication, and generic drugs S.44 Medicare Prescription Drug Negotiation Act S.1356 - Affordable Medicines Utilization Act of 2011 H.R.3342 - Affordable Medicines Utilization Act of 2011

LobbyistCovered position, as disclosed
CHRISTOPHER DAVIS —
JAMES M FENTON —
MARK D HENDRICKSON —
JASON R MONEY —
RALPH NEAS New —
JOHN SLOTMAN —

Contacted: Patent & Trademark Office (PTO); Congressional Budget Office (CBO); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); White House Office; Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); Medicare Payment Advisory Commission (MedPAC); Federal Trade Commission (FTC); U.S. Trade Representative (USTR); Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 1356 (112th), S. 44 (112th), H.R. 3342 (112th)

Pharmacy PHA

FY 2012 Budget, Implementation of Health Care Reform, Implementation of Generic Biologics, Prescription Drug Safety, Counterfeit Drugs/Import Safety/Pedigree, Prescription Drug Shortages, Authorized Generics, Prescription Drug Importation/Re-Importation, drug shortages, and generic drugs H.R. 2182 Generating Antibiotic Incentives Now Act of 2011 H.R.3026 - Safeguarding America's Pharmaceuticals Act of 2011 S.44 Medicare Prescription Drug Negotiation Act S.296 and H.R.2245 Preserving Access to Life-Saving Medication Act S.373 Fair Prescription Drug Competition Act S.1584 - Drug Safety and Accountability Act of 2011

LobbyistCovered position, as disclosed
CHRISTOPHER DAVIS —
JAMES M FENTON —
MARK D HENDRICKSON —
JASON R MONEY —
RALPH NEAS New —
JOHN SLOTMAN —

Contacted: Congressional Budget Office (CBO); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA); Patent & Trademark Office (PTO); Office of Management & Budget (OMB); U.S. Trade Representative (USTR); Commerce, Dept of (DOC); Medicare Payment Advisory Commission (MedPAC); Federal Trade Commission (FTC); White House Office; Health & Human Services, Dept of (HHS)

Bills named: H.R. 3026 (112th), S. 1584 (112th), H.R. 2182 (112th), S. 373 (112th), H.R. 2245 (112th), S. 44 (112th), S. 296 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.